Odomzo FDA Approval History
FDA Approved: Yes (First approved July 24, 2015)
Brand name: Odomzo
Generic name: sonidegib
Dosage form: Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: Basal Cell Carcinoma
Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).
Development timeline for Odomzo
Date | Article |
---|---|
Jul 24, 2015 | Approval FDA Approves Odomzo (sonidegib) for Locally Advanced Basal Cell Carcinoma |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.